Vivek Subbiah: Great to meet amazing people like Ram Arumugam
Vivek Subbiah shared a post by Ram Arumugam, Senior Manager of Business Operations | Genospaceon at McKesson on LinkedIn, adding the following:
“The ASCO24 annual meeting was awesome. Great to meet amazing & highly enthusiastic people like Ram Arumugam! Keep up the good work Ram. We need everyone in this field engaged to move the cancer needle.”
Quoting Ram Arumugam’s post:
“Honored and humbled to meet the esteemed Dr. Vivek Subbiah, MD at ASCO24. It was a tremendous eye-opening exchange and experience with the leader in cancer treatment and clinical trials, with an immense focus on personalized medicine and targeted therapies.
In his words: ‘Research should be the standard-of-care and the standard-of-care should be research’…simply powerful!”
Source: Vivek Subbiah/LinkedIn and Ram Arumugam/LinkedIn
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.
He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023